Orchid Pharma’s lenders reject Union Quimico’s bid

Lenders to bankrupt Orchid Pharma have called for a second round of bidding for the drug maker after they found the offer from the only eligible bidder in the first round — Union Quimico Farmacéutica — to be too low, two senior officials said.

The resolution professional who is in charge of the management of the Chennai-based company has set April 25 as the fresh date for submitting binding bids for the firm, said the officials who requested not to be named.

Two bids in the first round — from Ingen Capital and Fidelity Trading Corporation — were deemed ineligible.

“Although the bid of Union Quimico Farmacéutica was eligible, lenders were not interested since it offered just about Rs 600 crore payable over 3-6 years,” one of the officials said. Union Quimico is a subsidiary of Hyderabad-based Vivimed Labs.

Orchid Pharma, which is facing financial claims of Rs 3,500 crore, was in the second list of 28 companies that the RBI had mandated banks to refer to bankruptcy court by the end of December if lenders are unable restructure the loan.

It exports active pharmaceutical ingredients (APIs) of antibiotics and has two US Food and Drug Administration-approved manufacturing plants. It was referred to bankruptcy court by Lakshmi Vilas Bank in the middle of last year.

The committee of creditors of Orchid Pharma has now authorised the RP to go for a fresh round of bidding.

The RP has indicated that the resolution applicants who participated in the earlier rounds of bidding are also eligible to participate in this round of bidding According to experts, Orchid Pharma’s bankruptcy reflects the state of India’s API manufacturers.

The company had to sell assets to rein in debt. In 2012, it sold its penicillin business to US drug maker Hospira for $200 million. Though Indian drug makers are making their mark in formulation exports, API manufacturers have faced tough competition from Chinese rivals.

Almost 60% of APIs that Indian pharmaceutical companies use to make drugs comes from China. The state of small and medium-size API makers persuaded the government to set up a task force to impose curbs on imports of APIs.

  • Related Posts

    • Health
    • February 10, 2024
    • 11 views
    Appointment of CEO packs a Punch in NeuroEqulibrium’s Global Goal

    New Delhi: The ambition of NeuroEquilibrium gets a shot in the arm with the appointment of industry vetran Samit Verma as its CEO (Chief Executive Officer). Its global aspiration will…

    Millets reigned Supreme in International Symposium on Gut Health

    New Delhi: Millets reign supreme as gut health assumes most important aspect of the latest preventive and curative healthcare approach. This fact was writ large on Symposium on ‘Gut Health…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Lee Health develops natural capsule for effective Heart care

    Lee Health develops natural capsule for effective Heart care

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down